Related Experiment Videos
[ABO-incompatible nonmyeloablative allogeneic peripheral blood stem cell transplantation].
Wan-Jun Sun1, Mei Guo, Jian-Hui Qiao
1Department of Hematology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100039, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|March 8, 2005
Summary
ABO-incompatible nonmyeloablative allogeneic peripheral blood stem cell transplantation (NAST) is safe, showing no adverse effects on engraftment, GVHD, relapse, or survival. However, major ABO incompatibility may delay red blood cell recovery.
Area of Science:
- Hematology
- Immunology
- Transplantation
Context:
- Allogeneic stem cell transplantation requires HLA matching.
- ABO incompatibility presents a challenge in transplantation, potentially leading to hemolysis.
- Nonmyeloablative allogeneic peripheral blood stem cell transplantation (NAST) is an alternative approach.
Purpose:
- To investigate the impact of ABO incompatibility on HLA-matched NAST outcomes.
- To assess engraftment, hemolysis, GVHD, relapse, and survival in ABO-incompatible NAST.
Summary:
- A retrospective study compared 24 HLA-matched NAST cases (15 major ABO-incompatible, 9 minor) with 24 ABO-compatible controls.
- Grafts were depleted of erythrocytes for ABO-incompatible recipients. Successful engraftment occurred in 23 patients with delayed hemolysis in 2.
- While engraftment and survival were unaffected, major ABO incompatibility delayed erythropoiesis, with one case of pure red cell aplasia.
Impact:
- ABO-incompatible NAST is a viable and safe option when indicated, despite a potential delay in red blood cell recovery.
- Graft manipulation (erythrocyte depletion) mitigates immediate risks of hemolysis.
- This study supports the use of ABO-incompatible grafts in NAST, broadening donor options.